Lupus & antiphospholipid syndrome
The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab
Authors' conclusion
Immunization with the BNT vaccine is efficacious and safe for SLE patients treated with Belimumab.
Study context
- Population
- SLE patients treated with belimumab, Sheba Medical Center, Israel, receiving BNT162b2 COVID-19 vaccine10 with serologic assessment
- Participants
- 17 patients
- Outcome
- Immunogenicity (seroconversion) and safety of BNT vaccine, especially yield of a booster third dose
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Seropositivity
Seropositive after second dose
7 of 10
70%
Seroconverted only after third dose
2 of 3
Observational data: associations, not effects.
Further findings
- SLEDAI before vaccinations
- 4 ± 3.8
- SLEDAI after vaccinations
- 4 ± 2.7
- P
- P = 0.69
Safety
- Well tolerated with minimal adverse events and no disease flares
Original publication
The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab. Lupus. Published 23 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →